Toralgen, founded in Indianapolis, Indiana, is a preclinical stage biopharmaceutical company dedicated to revolutionizing drug delivery systems. Their core mission is to eliminate the challenges associated with oral drug delivery through their innovative nanopill technology. This technology utilizes a unique poly-bile nanoparticle platform that protects drugs, including biologics, through the stomach and intestines while retaining bioactivity. Toralgen's primary focus is on developing and commercializing human therapeutics that offer more effective and efficient oral delivery solutions.

Toralgen has garnered attention from notable investors and industry experts due to its groundbreaking approach to drug delivery. The company's key achievements include the successful development of their nanopill technology, which has the potential to replace traditional injections and improve patient compliance. By enhancing the bioavailability and localization of drug agents, Toralgen's innovations have the potential to significantly impact the biopharmaceutical industry and improve therapeutic outcomes for patients worldwide.